Enovis (ENOV): insider & executive buying
Enovis · Health Care · ref. ETF XLV · price $18.99
In short — 2 insiders bought Enovis over ~6 months (4 buys, total $476k, latest Sep 4, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Enovis's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$18.99-38.9% over range
Oct 14, 25low $17.43 · high $32.87Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 8 analysts
Latest insider buys on Enovis
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Sep 4, 26 | Engert Oliver | Chief Administrative Officer | 2,660 | $50k |
| Sep 4, 26 | McDonald Damien | CEO | 13,035 | $250k |
| Sep 2, 26 | Engert Oliver | Chief Administrative Officer | 7,598 | $150k |
| Jun 11, 26 | Engert Oliver | Chief Administrative Officer | 1,200 | $26k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Enovis's executives bought shares recently?
2 Enovis insider(s) bought $476k over ~6 months (latest Sep 4, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for ENOV?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Enovis? The JPI assistant answers using our backtest data.